Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Latest share price
SEK
20 Nov 2026 17:29 CET
Fair value range
SEK
30 Oct 2026
Market cap
SEK
m
EQL Pharma
Healthcare
2026-11-06
Q2 was significantly above expectations, although temporary factors contributed materially to the beat. The operational recovery is encouraging, with management more...
Post-Results Note
Erik Hultgård
Arvid Necander
Entering the next phase of recovery - Q2 review
Q2 2026/27 initial - significantly ahead on sales and margins
Restocking and easier comparables - Q2 preview
EQL Pharma
Healthcare
2026-11-05
Q2 beat our expectations significantly, partly driven by temporary sales contributions. Improving availability and strong adjusted margins are encouraging, although the...
News
Erik Hultgård
Arvid Necander
Entering the next phase of recovery - Q2 review
Q2 2026/27 initial - significantly ahead on sales and margins
Restocking and easier comparables - Q2 preview
EQL Pharma
Healthcare
2026-10-30
We expect a more favourable comparison and progress on restocking to support a return to sales growth in Q2 2026/27. We forecast a sequential improvement in the adj....
Pre-Results Note
Erik Hultgård
Arvid Necander
Entering the next phase of recovery - Q2 review
Q2 2026/27 initial - significantly ahead on sales and margins
Restocking and easier comparables - Q2 preview
Price
Fair range high value
Fair range low value
Year
2024
2025
2026e
2027e
2028e
EPS
1.48
0.42
0.30
2.18
3.65
EPS (Adj.)
1.56
0.86
1.48
2.18
3.65
Sales Growth
41.39%
15.83%
17.51%
21.78%
21.98%
EPS Growth (Adj.)
53.27%
-44.42%
71.52%
47.20%
67.40%
P/E
14.6
51.0
72.6
9.9
5.9
P/E (Adj.)
13.9
25.0
14.6
9.9
5.9
EV/EBITA
14.8
20.6
25.7
9.5
6.1
EV/EBITDA
12.4
13.7
14.7
7.3
5.0
Learn more
Sector
Healthcare
Country
Sweden
Tickers
EQL@SS, EQL.ST
CEO
Axel Schörling
CFO
Anna Jönsson
Webpage
www.eqlpharma.com
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB